Genvigir, Fabiana Dalla Vecchia; Campos-Salazar, Antony Brayan 
; Felipe, Claudia Rosso ; Silva Junior, Helio Tedesco ; Pestana, José Osmar Medina ; Doi, Sonia de Quateli; Cerda, Alvaro; Hirata, Mario Hiroyuki ; Herrero, María José; Hirata, Rosario Dominguez Crespo
Source: Pharmacogenomics. Unidade: FCF
Subjects: TRANSPLANTE DE RIM, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GENVIGIR, Fabiana Dalla Vecchia et al. CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy. Pharmacogenomics, v. 21, n. 1, p. 7-21, 2020Tradução . . Disponível em: https://doi.org/10.2217/pgs-2019-0120. Acesso em: 09 nov. 2024.APA
Genvigir, F. D. V., Campos-Salazar, A. B., Felipe, C. R., Silva Junior, H. T., Pestana, J. O. M., Doi, S. de Q., et al. (2020). CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy. Pharmacogenomics, 21( 1), 7-21. doi:10.2217/pgs-2019-0120NLM
Genvigir FDV, Campos-Salazar AB, Felipe CR, Silva Junior HT, Pestana JOM, Doi S de Q, Cerda A, Hirata MH, Herrero MJ, Hirata RDC. CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy [Internet]. Pharmacogenomics. 2020 ; 21( 1): 7-21.[citado 2024 nov. 09 ] Available from: https://doi.org/10.2217/pgs-2019-0120Vancouver
Genvigir FDV, Campos-Salazar AB, Felipe CR, Silva Junior HT, Pestana JOM, Doi S de Q, Cerda A, Hirata MH, Herrero MJ, Hirata RDC. CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy [Internet]. Pharmacogenomics. 2020 ; 21( 1): 7-21.[citado 2024 nov. 09 ] Available from: https://doi.org/10.2217/pgs-2019-0120
